These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 12052143)

  • 61. [Pharmacologic and toxicologic results in genetic polymorphisms (review)].
    Kohút A; Kalina I
    Cesk Fysiol; 1998 Dec; 47(4):172-84. PubMed ID: 10535175
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Polymorphism in drug metabolism--implications for drug toxicity.
    Smith RL
    Arch Toxicol Suppl; 1986; 9():138-46. PubMed ID: 3468894
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Molecular genetics of the N-acetyltransferases.
    Grant DM
    Pharmacogenetics; 1993 Feb; 3(1):45-50. PubMed ID: 8097948
    [No Abstract]   [Full Text] [Related]  

  • 64. Genetic susceptibility to adverse effects of drugs and environmental toxicants. The role of the CYP family of enzymes.
    Ingelman-Sundberg M
    Mutat Res; 2001 Oct; 482(1-2):11-9. PubMed ID: 11535244
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Smokers and breast cancer. 'Chemical individuality' and cancer predisposition.
    Lin HJ
    JAMA; 1996 Nov; 276(18):1511-2. PubMed ID: 8903264
    [No Abstract]   [Full Text] [Related]  

  • 66. Genetic polymorphisms and breast cancer risk.
    Zahm SH; Figgs LW; Bulbulyan M; Zaridze DG
    JAMA; 1997 Feb; 277(7):533-4; author reply 534. PubMed ID: 9032158
    [No Abstract]   [Full Text] [Related]  

  • 67. Pharmacogenetic screening and therapeutic drugs.
    Steimer W; Potter JM
    Clin Chim Acta; 2002 Jan; 315(1-2):137-55. PubMed ID: 11728416
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Insights into the phylogeny or arylamine N-acetyltransferases in fungi.
    Martins M; Dairou J; Rodrigues-Lima F; Dupret JM; Silar P
    J Mol Evol; 2010 Aug; 71(2):141-52. PubMed ID: 20676885
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Drugs and genes.
    Lancet; 1973 Aug; 2(7823):247-8. PubMed ID: 4124432
    [No Abstract]   [Full Text] [Related]  

  • 70. PtmC Catalyzes the Final Step of Thioplatensimycin, Thioplatencin, and Thioplatensilin Biosynthesis and Expands the Scope of Arylamine
    Zheng CJ; Kalkreuter E; Fan BY; Liu YC; Dong LB; Shen B
    ACS Chem Biol; 2021 Jan; 16(1):96-105. PubMed ID: 33314918
    [TBL] [Abstract][Full Text] [Related]  

  • 71. 1998 International Meeting on the Arylamine N-Acetyltransferases: synopsis of the workshop on nomenclature, biochemistry, molecular biology, interspecies comparisons, and role in human disease risk.
    Ilett KF; Kadlubar FF; Minchin RF
    Drug Metab Dispos; 1999 Sep; 27(9):957-9. PubMed ID: 10460790
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Genetic polymorphisms and breast cancer risk.
    Kazandjian VA
    JAMA; 1997 Feb; 277(7):533; author reply 534. PubMed ID: 9032157
    [No Abstract]   [Full Text] [Related]  

  • 73. [The biochemical basis of toxic actions of drugs and other xenobiotics].
    Nuhn P
    Pharm Unserer Zeit; 1993 Jul; 22(3):119-33. PubMed ID: 8367516
    [No Abstract]   [Full Text] [Related]  

  • 74. Biotransformation of Drugs and other Xenobiotics as Key Modulator of Toxicity.
    Orhan H
    Curr Drug Metab; 2021; 22(8):582-583. PubMed ID: 34636292
    [No Abstract]   [Full Text] [Related]  

  • 75. Influence of polymorphic N-acetyltransferases on non-malignant spontaneous disorders and on response to drugs.
    Ladero JM
    Curr Drug Metab; 2008 Jul; 9(6):532-7. PubMed ID: 18680473
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Effect of genetic factors and illnesses on drug efficacy].
    Feuring M; Wehling M; Falkenstein E
    Internist (Berl); 2000 Apr; 41(4):332-7. PubMed ID: 10798180
    [No Abstract]   [Full Text] [Related]  

  • 77. Gut microbiome interactions with drug metabolism, efficacy, and toxicity.
    Wilson ID; Nicholson JK
    Transl Res; 2017 Jan; 179():204-222. PubMed ID: 27591027
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Xenobiotic sulphation and its variability during inflammation: a factor in adverse drug reactions?
    Waring RH; Harris RM; Hunter JO; Mitchell SC
    Curr Drug Metab; 2013 Mar; 14(3):361-5. PubMed ID: 23176089
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Genetic polymorphisms in human drug metabolic enzymes.
    Miller MS; McCarver DG; Bell DA; Eaton DL; Goldstein JA
    Fundam Appl Toxicol; 1997 Nov; 40(1):1-14. PubMed ID: 9398483
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Development of analytical technology in pharmacogenetic research.
    Daly AK
    Naunyn Schmiedebergs Arch Pharmacol; 2004 Jan; 369(1):133-40. PubMed ID: 14513205
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.